Enzalutamide for treating hormone-sensitive metastatic prostate cancer – guidance (TA712)

NICE recommend enzalutamide plus androgen deprivation therapy as an option for treating hormone-sensitive metastatic prostate cancer in adults.

National Institute for Health and Care Excellence